Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
You may also be interested in...
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
Filings for the twice-yearly anti-PCSK9 injection under a partnership with Alnylam are on track, including a fourth quarter submission in the US. Detailed ORION-9 and ORION-10 data will be presented at AHA in November.
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.